anifrolumab   Click here for help

GtoPdb Ligand ID: 8258

Synonyms: anifrolumab-fnia | MDX-1333 | MEDI-546 | Saphnelo®
Approved drug Immunopharmacology Ligand
anifrolumab is an approved drug (FDA (2021), EMA (2022))
Compound class: Antibody
Comment: Anifrolumab is a monoclonal antibody targeting IFNAR1 (the receptor for α, β and ω interferons), that was developed by the MedImmune subsidiary of AstraZeneca as a treatment for systemic lupus erythematosus (SLE).
Peptide sequence and structural information for this antibody are available from its IMGT/mAb-db record. [3]. Sequence BLAST using the heavy and light chain variable regions of anifrolumab provides 100% matches to sequences that are claimed in patent US7662381 [3]. The sequence matches identify anifrolumab as clone 11E2 in the patent.
Click here for help
Bioactivity Comments
Anifrolumab inhibits the antiproliferative effect of IFNω on Daudi cells with an EC50 value of 0.3nM [3].
Selectivity at catalytic receptors
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
interferon α/β receptor 1 Primary target of this compound Hs Antibody Binding >10.0 pKd - 3
pKd >10.0 (Kd <1x10-10 M) [3]